Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Cannabis

Study: Given the choice, patients will reach for marijuana over prescribed opioids

by University of British Columbia
February 27, 2017
in Cannabis, Psychopharmacology
Photo credit: Martijn

Photo credit: Martijn

Share on TwitterShare on Facebook

Chronic pain sufferers and those taking mental health meds would rather turn to cannabis instead of their prescribed opioid medication, according to new research by the University of British Columbia and University of Victoria. “This study is one of the first to track medical cannabis use under the new system of licensed producers, meaning that all participants had physician authorization to access cannabis in addition to their prescription medicines,” says UBC Assoc. Prof. Zach Walsh, co-author of the study.

The study tracked more than 250 patients with prescribed medical cannabis–people treated for conditions such as chronic pain, mental health and gastrointestinal issues. Overall, 63 per cent of respondents reported using cannabis instead of their prescription drugs, which included opioids (to treat pain), benzodiazepines (sedatives) and anti-depressants.

Study lead Philippe Lucas is vice-president of Patient Research and Access at Tilray, a federally authorized medical cannabis production and research company, and a graduate fellow at the University of Victoria Centre for Addictions Research of BC. Lucas suggests the main reasons for the switch to cannabis from prescribed meds is due to reduced side effects, better symptom management and a feeling that cannabis is safer than prescription drugs.

Walsh goes on to suggest cannabis may have an important role to play in addressing the problematic use of pharmaceutical medications such as opioids.

In 2001, Canada became one of the first nations to develop a program to allow access to cannabis for medical purposes. As of August 2016 more than 30 federally authorized licensed producers of cannabis provided product to more than 65,000 patients.

“Further research into how well cannabis works compared to the accepted front-line treatments is warranted,” says Walsh. “Additionally, long-term research into the potential impact of the cannabis substitution on the quality of patient’s lives is ongoing.”

The study, published in International Journal of Drug Policy, was funded by Tilray.

Google News Preferences Add PsyPost to your preferred sources
Previous Post

Do you look like your name? People can match names to faces of strangers with surprising accuracy

Next Post

Dogs and toddlers show similarities in social intelligence

RELATED

Democrats dislike Republicans more than Republicans dislike Democrats, studies find
Ayahuasca

A single dose of DMT reverses depression-like symptoms in mice by repairing brain circuitry

March 8, 2026
Stimulant medications normalize brain structure in children with ADHD, study suggests
ADHD Research News

Long-term ADHD medication use does not appear to permanently alter the developing brain

March 5, 2026
Hemp-derived cannabigerol shows promise in reducing anxiety — and maybe even improving memory
Alcohol

Using cannabis to cut back on alcohol? Your working memory might dictate if it works

March 5, 2026
New psychology research flips the script on happiness and self-control
Cannabis

Exploring the motivations for cannabis use during sex

March 4, 2026
Chocolate lovers’ brains: How familiarity influences reward processing
Cognitive Science

A single dose of cocoa flavanols improves cognitive performance during aerobic exercise

March 4, 2026
Scientists discover psychedelic drug 5-MeO-DMT induces a state of “paradoxical wake”
Ayahuasca

Scientists discover psychedelic drug 5-MeO-DMT induces a state of “paradoxical wake”

March 4, 2026
New research: AI models tend to reflect the political ideologies of their creators
Neuroimaging

Psilocybin produces different behavioral and brain-altering effects depending on the dose

February 26, 2026
Consumption of gluten harms the hypothalamus region of the brain in male mice and may lead to obesity, study finds
Ketamine

Ketamine blocks the short-term anxiety and social withdrawal linked to adolescent social defeat

February 25, 2026

STAY CONNECTED

LATEST

Therapists test an AI dating simulator to help chronically single men practice romantic skills

Women with tattoos feel more attractive but experience the same body anxieties in the bedroom

Misophonia is strongly linked to a higher risk of mental health and auditory disorders

Brain scans reveal the unique brain structures linked to frequent lucid dreaming

Black Lives Matter protests sparked a short-term conservative backlash but ultimately shifted the 2020 election towards Democrats

Massive global study links the habit of forgiving others to better overall well-being

Neuroscientists have pinpointed a potential biological signature for psychopathy

Supportive relationships are linked to positive personality changes

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions
  • Do not sell my personal information

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc